Fecal microbiota profiles as a diagnostic biomarkers in cirrhosis and hepatocellular carcinoma and the impact of life style and nutrition 
EASL LiverTree™, Michal Safran, 207342
Gut microbes mediate liver fibrosis in chimeric mice with human hepatocytes persistently infected with hepatitis B virus
EASL LiverTree™, Masaya Sugiyama, 207343
Serum CXCL14 chemokine as a biomarker during murine acute and chronic hepatitis
EASL LiverTree™, Christelle Devisme, 207358
Autophagy-related liver enzymes in chronic liver disease
EASL LiverTree™, Dimitrios Samonakis, 207359
Clinical presentation, natural history and treatment of hepatic sarcoidosis: a case-series of 39 patients with histologically proven hepatic sarcoidosis
EASL LiverTree™, Malte Wehmeyer, 207361
Upregulation of miR-34c driven by JNK and FOXO3 in livers expressing mutant Z alpha1-antitrypsin
EASL LiverTree™, Pasquale Piccolo, 207362
The PR interval in the fetal electrocardiogram is significantly prolonged in severe Intrahepatic Cholestasis of Pregnancy and potentially normalised by UDCA therapy
EASL LiverTree™, Tharni Vasavan, 207376
EASL LiverTree™, Galina Volynets, 207377
High caloric nutrition promotes hepatocellular damage and steatohepatitis in Wilson disease rats via amplified mitochondrial damage.
EASL LiverTree™, Claudia Einer, 207379
Evaluation of the New criteria in the diagnosis of cystic fibrosis liver disease
EASL LiverTree™, Iliana Mani, 207395
Prognostic Value of 2D-Shear Wave Elastography(2D-SWE) for staging cirrhosis in chronic liver diseases (CLD) in two severity classes according to liver-related complications
EASL LiverTree™, Priscila Pollo Flores, 207397
Reliability criteria for liver stiffness measurement with ARFI
EASL LiverTree™, Jérôme Boursier, 207398
Performance of shear-wave elastography to detect high-risk esophageal varices in cirrhosis is improved by spleen stiffness estimation
EASL LiverTree™, Seong Hee Kang, 207413
Non-invasive estimation of hepatic fibrosis and steatosis: comparison of 2D shear-wave elastography and acoustic structure quantification with transient elastography and controlled attenuation parameter
EASL LiverTree™, Valentin Blank, 207414
CT-driven Model for End-Stage Liver Disease: Comparison of Survival Prediction with MELD score
EASL LiverTree™, Ji Eun Lee, 207415
Which is the chance for type 2 diabetes patients to develop severe liver disease?
EASL LiverTree™, Ioan Sporea, 207431
Intelligent Liver Function diagnostic pathway - Relevance of alanine transaminase normal values.
EASL LiverTree™, Emma Robinson, 207432
Phenotypic characteristics and improvement of liver stiffness measurement during follow-up in patients with Wilson's disease
EASL LiverTree™, Razvan Iacob, 207435
IsFood-intake a Confusing Factor For Liver Stiffness Evaluation by2D-SWE in Normal Subjects?
EASL LiverTree™, Alina Popescu, 207436
Sulfatase 2 Antagonizes Starvation-Induced Autophagy in Hepatocellular Carcinoma
EASL LiverTree™, Paola Alejandra Romecin Duran, 207452
In vivo knockdown of Plk1 using a novel breakable mesoporous silica particle siRNA carrier reduces tumor growth in an orthotopic xenograft mouse model of hepatocellular carcinoma
EASL LiverTree™, Antonio Saviano, 207453
EASL LiverTree™, Guillermo Fernández Varo, 207454
Hepatocyte c-Jun N-terminal kinases determine cell fate and carcinogenesis in NEMO-deficient mice
EASL LiverTree™, Mohamed Ramadan Mohamed, 207455
Circulating exosomal non-coding RNAs as prognostic biomarkers in human hepatocellular carcinoma
EASL LiverTree™, Yu Rim Lee, 207470
Molecular characterization of autophagic and apoptotic signaling induced by Sorafenib in liver cancer cells: In vitro and in vivo studies
EASL LiverTree™, M. Ángeles Rodríguez-Hernández, 207472
Defective NKp30-mediated function in hepatocellular carcinoma-infiltrating NK cells
Cost-effective target sequencing panel for hepatocellular carcinoma mutational screening
EASL LiverTree™, Charlotte Ng, 207490
Canonical inhibition of TransformingGrowth Factor β Receptor 1 triggers proliferation of hepatocellular carcinoma andis associated with Toll Like Receptor 7 upregulation.
EASL LiverTree™, Fatma Mohamed, 207492
EASL LiverTree™, Elia Gigante, 207506
Aspecific ECM composition regulates Smad dependent - TGFbeta1-induced EMT response in HepG2 cells engineered in cirrhotic and healthyliver 3D scaffolds
EASL LiverTree™, Krista Rombouts, 207508
Analysis of HBV DNA Integration in Tumor and non-Tumor Liver Tissues by a High-Throughput Viral Integration Detection Method.
EASL LiverTree™, Deborah D'Aliberti, 207509
New targets for hepatocellular carcinoma therapy: the Myc/PRMT5/RNAP II circuit
EASL LiverTree™, Cristiana Porcu, 207510
The area of the paarspinal muscle mass in patients with cirrhosis although not different from controls predicts cirrhosis-associated complications and death in a large mono-centric study
EASL LiverTree™, Cornelius Engelmann, 207526
TLR9-mediated immune sensing of bacterial DNA in decompensated cirrhosis is stage-dependent
EASL LiverTree™, Eihab Al-Herwi, 207527
Longitudinal outcomes of the application of non-selective beta-blockers in portal hypertension: Are low-dose non-selective beta-blockers effective?
EASL LiverTree™, Seong Hee Kang, 207528
Antibiotic-Associated Disruption of Microbial Composition and Functionality is Restored after Fecal Transplant in Cirrhosis
EASL LiverTree™, Jasmohan S Bajaj, 207541
Beta-Blocker use in Cirrhosis is Independently Associated with Minimal Hepatic Encephalopathy
EASL LiverTree™, Jasmohan S Bajaj, 207542
High-dose but not low-dose enoxaparin substantially improves survival in cirrhotic patients with portal vein thrombosis
EASL LiverTree™, Laura Turco, 207544
Propranolol Treatment Associated with Better Survival and Reduced Sepsis in Cirrhotic Patients with Hepatic Encephalopathy
EASL LiverTree™, Pei Chang Lee, 207557
Six-minute Walk Test and Sarcopenia in Predicting Mortality in Patients with Cirrhosis
EASL LiverTree™, ThucNhi Dang, 207558
The effect of primary prophylaxis therapy for large esophageal varices in patients with hepatocellular carcinoma 
EASL LiverTree™, Hsiao Sheng Lu, 207559
Characteristics of bone marrow drived mesenchymal stem cells in patients with liver cirrhosis
EASL LiverTree™, Ki Tae Suk, 207560
Increasing Burden of Hepatic Encephalopathy among Hospitalized Adults, With Significantly Higher Risk of In-Hospital Mortality in African Americans: An Analysis of the 2007-2013 Nationwide Inpatient Sample
EASL LiverTree™, Grishma Hirode, 207575
Health care costs are double for non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH) patients with compensated cirrhosis (CC) who progress to end-stage liver disease (ESLD)
EASL LiverTree™, Rohit Loomba, 207576
High real-world healthcare costs in non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH) compensated cirrhosis (CC)patients with and without type-2 diabetes mellitus (DM): A large German database study
EASL LiverTree™, Ali Canbay, 207577
Functional polymorphisms of innate immunity receptors are not risk factors for non-SBP type bacterial infections in cirrhosis
EASL LiverTree™, Tamas Tornai, 207578
Terlipressin for variceal bleeding induces severe plasma sodium disturbances in non-cirrhotic portal hypertension
EASL LiverTree™, Peter Lykke Eriksen, 207593
Outcome after the use of SX-ELLA Danis bleeding stents for refractory variceal bleeding- a Vienna Multicenter Experience
EASL LiverTree™, Nikolaus Pfisterer, 207594
The beneficial effects of non-selective betabockers in secondary prophylaxis are most pronounced in patients without refractory ascites
EASL LiverTree™, Nikolaus Pfisterer, 207595
Hemodynamic disturbances across different stages of decompensated cirrhosis and influencie on outcomes
EASL LiverTree™, Marta García Guix, 207597
Cardiac fibrosis and coronary atherosclerosis in cirrhosis. Indications of cirrhotic cardiomyopathy?
EASL LiverTree™, Signe Wiese, 207611
The role of bile acids in the development of structural myocardial changes and cardiac dysfunction in patients with cirrhosis
EASL LiverTree™, Signe Wiese, 207612
Hepatopulmonary syndrome: a spontaneously reversible condition? Variability in prevalence in a prospective follow-up study of cirrhotic patients
EASL LiverTree™, Aurelia Chiricuta, 207613
Is obesity an additional negative factor in sarcopenic cirrhotic patients?
EASL LiverTree™, Daria D'Ambrosio, 207614
Gender differences regarding sarcopenia development in  chronic liver disease
EASL LiverTree™, Atsushi Hiraoka, 207628
Assessment of subclinical hepatic encephalopathy by using EncephalApp Stroop test and brain MRI
EASL LiverTree™, Maria C. Speranta Iacob, 207629
Impact of antibiotic prophylaxis of spontaneous bacterial peritonitis on colonization and infections with multidrug-resistant bacteria
EASL LiverTree™, Marcus Maximilian Mücke, 207630
The Indication, Dosage and Duration of Proton Pump Inhibitors in Liver Cirrhosis 
EASL LiverTree™, Marianne De Roza, 207631
High Mortality Rate in HBV-related Cirrhosis Patients with HEV Superinfection
EASL LiverTree™, Tai-Chung Tseng, 207647
Clinical features and outcomes of hepatitis E in patients with underlying chronic liver disease: a respective case-control study
EASL LiverTree™, Yijin Wang, 207648
Risk factors of hepatitis E related liver failure: a restrospective case-control study
EASL LiverTree™, Yijin Wang, 207649
The role of hepatitis E in acute non-traumatic neuropathy in China: a prospective case-control study
EASL LiverTree™, Yijin Wang, 207650
LTPprodrug technology offers new generation nucleotide antiviral agents 
EASL LiverTree™, Lin Zhi, 207665
Conservation and variation of the hepatitis E virus open reading frame 2 proteome
EASL LiverTree™, Shaoshi Zhang, 207666
Mutations in HCV NS3 but no Sec14L2 variants alter HCV RNA replication of natural occuring viruses in cell culture
EASL LiverTree™, Sandra Ciesek, 207667
Expanding the donor pool- decontamination of HCV RNA positive kidneys with methylene blue
EASL LiverTree™, Sandra Ciesek, 207668
Post transcriptional regulation of Hepatitis B virus in a prospective cohort of chronically infected patients
EASL LiverTree™, Aurélie Schnuriger, 207682
Murine hepatocytes with humanized sodium taurocholat polypeptide (NTCP) limit HDV infection in vivo independent of adaptive immune responses
EASL LiverTree™, Marc Luetgehmann, 207684
Antiviral properties and liver specific delivery of a TLR1/2 ligand in HBV-infected in vitro and in vivo models
EASL LiverTree™, Julie Lucifora, 207685
Whole Genome Viral Sequencing Reveals Subgenotype Specific Dynamics of Antiviral Treatment Response in HBeAg Positive and Treatment Naive Chronic Hepatitis B Patients
EASL LiverTree™, Ondrej Podlaha, 207699
Control of glycokinase activity by the HCV protein NS5A increases lipogenesis
EASL LiverTree™, Olivier Diaz, 207700
Evolution and persistence of resistance-associated substitutions of hepatitis c virus after daclatasvir plus asunaprevir treatment failures
EASL LiverTree™, Yechan Jeong, 207701
FXR agonist GW4064 represses HBV replication in adult but not in young C3H/HeN mice after HBV transduction with rAAV2/8-HBV
EASL LiverTree™, Patrice André, 207702
Hepatitis E virus replication and interferonresponse in human placental-derived cells
EASL LiverTree™, Patrick Behrendt, 207717
Are there different profiles in microRNA expression in HBV/HDV co-infected patients reflecting plasma HBsAg and HBcrAg concentrations?
EASL LiverTree™, Ivana Carey, 207718
Dimerization:  A  structural feature for the protection of Hepatitis E virus capsid protein against trypsinization
EASL LiverTree™, Wenjuan Wei, 207719
The correlations between HBV markers in sera and HBVcccDNA for genotypes
EASL LiverTree™, Takeshi Matsui, 207720
The RNA genome of hepatitis E virus robustly triggers antiviral interferon response
EASL LiverTree™, Wenshi Wang, 207736
Normalization of NK cell phenotype is delayed after successful interferon-free therapy in cirrhotic patients with chronic HCV infection. 
EASL LiverTree™, Elena Perpinan Mas, 207738
Transcriptome profiling of hepatitis B virus-infected human hepatocyte derived from chimeric mice with humanized liver
EASL LiverTree™, Shingo Nakamoto, 207739
Alcoholic Liver Disease replaces HCV Infection as the Leading Indication for Liver Transplantation in the United States 
EASL LiverTree™, George Cholankeril, 207755
Individualized prediction of the risk of liver-related death in patients with alcoholic cirrhosis
EASL LiverTree™, Astrid Marot, 207756
Liver transplantation for alcoholic hepatitis: a systematic review with meta-analysis
EASL LiverTree™, Astrid Marot, 207757
Hepatoprotective Biomarkers, Amphiregulin and Soluble Fas, IncreaseDuring ELAD Treatment in Alcoholic Hepatitis Subjects
EASL LiverTree™, Jason Lapetoda, 207771
The use of proton pump inhibitors among patients with alcoholic cirrhosis is not related with increased risk of death
EASL LiverTree™, Ulrich Bang, 207772
miRNA regulation of macrophage M1/M2 polarization of Kupffer cells and PBMCs in alcoholic liver disease
EASL LiverTree™, Adam Kim, 207773
The correlation of obesity with morbidity and mortality in alcoholic hepatitis. 
EASL LiverTree™, yasir yasiralazzawi, 207774
Histological severity is related to cardiovascular events in lean but not in overweight and obese subjects with NAFLD
EASL LiverTree™, Alexandra Feldman, 207789
Characterization of Patients with Both Alcoholic and Nonalcoholic Fatty Liver Disease (BAFLD) in a Large United States Cohort
EASL LiverTree™, Naim Alkhouri, 207790
Increased gut permeability is associated with oxidative stress in patients with NAFLD
EASL LiverTree™, Francesco Baratta, 207791
Increasing Trend forHepatocellular Carcinoma (HCC) Linked to Nonalcoholic Fatty Liver Disease(NAFLD) in the United States
EASL LiverTree™, Ethan Miller, 207792
The relationship between NAFLD and breast cancer: High prevalence and poor prognosis.
EASL LiverTree™, Young-Sun Lee, 207807
Impact of duodenal-jejunal bypass liner on non-alcoholic fatty liver disease
EASL LiverTree™, Thomas Karlas, 207808
Nonalcoholic fatty liver disease in the first trimester and subsequent development of gestational diabetes: A prospective cohort study
EASL LiverTree™, Won Kim, 207809
Plasma cells in non-alcoholic steatohepatitis correlates with disease activity
EASL LiverTree™, Mehul Lamba, 207810
Low-moderate alcohol use is associated with a  lower prevalence of non-alcoholic fatty liver disease in Hispanics/Latinos living in the US:  Results from the Hispanic Community Health Study/Study of Latinos (HCHS/SOL)
EASL LiverTree™, Aynur Unalp-Arida, 207823
Even modest alcohol use is associated with greater steatosis on magnetic resonance imaging in patients with NAFLD - a pilot study
EASL LiverTree™, Veeral Ajmera, 207824
Role of nutritional intake on clinical presentation of lean and overweight NAFLD
EASL LiverTree™, Rosa Lombardi, 207825
Non-alcoholic fatty liver disease is omega-6 fatty acids diet dipendent in a group of obese children
EASL LiverTree™, Anna Mantovani, 207826

Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.

Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.

Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.

Save Settings